“Universal” CRISPR-edited T cells improve resistant leukaemia
Children with leukaemia were successfully treated with first-in-human "universal" CRISPR-edited T-cells, by researchers at Great Ormond Street Hospital and University College London.
List view / Grid view
News
UK £62 billion behind in R&D global investment share, report reveals
The IPPR urges the UK government to increase R&D funding to strengthen economic growth and restore the UK’s leading global position.
Microneedle patches designed by AI restore hair in balding mice
Using AI, researchers have produced a nanozyme treatment for regenerating hair in mice, delivered via a microneedle.
New therapy for anaemic myelodysplastic cancer patients
Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
CPHI report predicts huge funding overhang to drive contract services growth
Private equity overhang to fuel CDMO valuations and expansions, while venture capital overhang will fuel continued demand for services in spite of adverse global conditions.
Biopharma successful in achieving climate-related goals, report finds
A report shows two Big Pharma companies made the top 10 in the FTSE sustainability leaderboard, yet progress against climate goals has stalled since COP26.
EMA’s PRAC confirms recommendation to withdraw amfepramones
The EMA’s safety board verifies that amfepramone-containing products for obesity should not be sold, due to higher-associated health risks.
EMA validates AbbVie lymphoma bispecific antibody application
AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.
Outsourcing APIs put EU patients at risk
Teva warns APIs could disappear from European factories in five to 10 years if the industry does not see outsourcing essential medicine manufacture as risky.
First patient receives new engineered mRNA epigenetic
OTX-2002, a programmable epigenetic medicine is the first mRNA therapy to target MYC dysregulation and could treat hepatocellular carcinoma.
CPHI report predicts biologics outsourcing to surge in 2023
Report out ahead of CPHI Frankfurt predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls.'
Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
$3 trillion growth reported for biotech sector
A report reveals US job growth in the biotech industry has risen 11 percent since 2018, tipping the COVID-19 pandemic as the key driver.
NICE recommends first oral GnRH antagonist for uterine fibroids
Ryeqo, a one-per-day oral drug for adults with moderate-to-severe symptoms of uterine fibroids has been given the green light by NICE.
